Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 3/20 | 0.38 |
| ▸ | NT5E | P21589 | 7/20 | 0.34 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | NPEPPS | P55786 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19859850 | 0.86 | TYMP (0.39) | TYMPNT5EADORA2AADORA2B | |
| SCHEMBL21046369 | 0.85 | TYMP (0.37) | TYMPNT5EADORA2AADORA2B | |
| SCHEMBL19859710 | 0.84 | TYMP (0.38) | TYMPNT5EADORA2AADORA2B | |
| SCHEMBL21046387 | 0.82 | ADORA2A (0.34) | NT5ENPEPPSANPEPLMNAADORA2A | |
| SCHEMBL21046383 | 0.82 | ADORA2A (0.33) | NT5ENPEPPSANPEPLMNAADORA2A | |
| SCHEMBL19859764 | 0.76 | ADORA1 (0.39) | ADORA2AADORA2B | |
| SCHEMBL30138547 | 0.76 | ADORA1 (0.39) | ADORA2AADORA2B | |
| SCHEMBL21046386 | 0.75 | TYMP (0.34) | TYMPADORA2AADORA2B | |
| SCHEMBL19859763 | 0.74 | TYMP (0.33) | TYMPNT5EADORA2AADORA2B | |
| SCHEMBL19859810 | 0.74 | TYMP (0.33) | TYMPNT5EADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | TYMP 11/4885NT5E 13/4885TRDMT1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.